Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tumor and serum levels of murine IL-12.

Published byJøran Ask Modified over 4 years ago

Similar presentations

Presentation on theme: "Tumor and serum levels of murine IL-12."— Presentation transcript:

1 Tumor and serum levels of murine IL-12.
Tumor and serum levels of murine IL-12. Murine IL-12 (mIL-12) levels were measured in the serum (□) and homogenized tumor samples (•) using ELISA at various time points. The units were picogram per milliliter for the serum and picogram per milligram for the tumor. Horizontal line, lower limit of detection of IL-12 in this assay. A, 109 pfu/tumor; B, 1010 pfu/tumor; C, 1011 pfu/tumor. Farzan Siddiqui et al. Mol Cancer Ther 2007;6: ©2007 by American Association for Cancer Research

Download ppt "Tumor and serum levels of murine IL-12."

Similar presentations

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Antitumor activity of BAY in patient-derived tumor models.

Antitumor activity of BAY in patient-derived tumor models.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Activity of MAC-321 (i. v. and p. o

Activity of MAC-321 (i. v. and p. o
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Risk of PTC associated with serum concentrations of TSH and thyroid hormones among females, stratified by tumor size. *, Conditional logistic regression,

Risk of PTC associated with serum concentrations of TSH and thyroid hormones among females, stratified by tumor size. *, Conditional logistic regression,
A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =

A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =
Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Fig. 1. Detection of circulating tumor DNA in CRPC patients.
Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.

Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.
Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.

Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.
Immunohistochemical analyses of SHH expression levels in nonmalignant prostate and adenocarcinoma tissues. Immunohistochemical analyses of SHH expression.

Immunohistochemical analyses of SHH expression levels in nonmalignant prostate and adenocarcinoma tissues. Immunohistochemical analyses of SHH expression.
Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.

Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.
The expression of SPINDLIN1 in cancer tissues.

The expression of SPINDLIN1 in cancer tissues.
Expression analysis of IGFBP-3 using human whole-genome microarray.

Expression analysis of IGFBP-3 using human whole-genome microarray.
Change in antibody-dependent cellular cytotoxicity between baseline and day 15, day 30, and day 45 for cohort 1 and 2 versus cohort 3. Change in antibody-dependent.

Change in antibody-dependent cellular cytotoxicity between baseline and day 15, day 30, and day 45 for cohort 1 and 2 versus cohort 3. Change in antibody-dependent.
Variation in dUTPase expression in cell lines.

Variation in dUTPase expression in cell lines.
Effect of HA on hematopoietic recovery in tumor-bearing mice.

Effect of HA on hematopoietic recovery in tumor-bearing mice.
PTENP1 sensitizes renal cancer cells to chemotherapy.

PTENP1 sensitizes renal cancer cells to chemotherapy.
A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control.

A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control.

Similar presentations

Ads by Google